ASX Share rice
Tue 21 Sep 2021 - 08:19:am (Sydney)

ZLD Share Price

ZELIRA THERAPEUTICS LIMITEDZLDPharmaceuticals, Biotechnology & Life Sciences

ZLD Company Information

Name:

Zelira Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

101 St Georges Terrace Perth WA Australia 6000

Phone:

61 8 6558 0886

Founder & Chairman:

Mr. Osagie O. Imasogie Esq.

MD, Global CEO & Director:

Dr. Oludare Odumosu

Company Sec.:

Mr. Timothy Ryan Slate

Clinical Trial Consultant:

Dr. Patty Washer

Company Overview:

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; the Children's Hospital of Philadelphia (CHOP) on opioid reduction study; HAPA Pharm BV; and Ethicann. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was founded in 2003 and is headquartered in Perth, Australia.

ZLD Share Price Information

Shares Issued:

1.19B

Market Capitalisation:

$47.61M

Revenue (TTM):

$663.32K

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.007

Operating Margin (TTM):

$-14.14

Return On Assets (TTM):

$-0.16

Return On Equity (TTM):

$-0.24

Quarterly Revenue Growth (YOY):

-0.934

Gross Profit(TTM):

$435.09K

Diluted Earnings Per Share (TTM):

$-0.007

ZLD CashFlow Statement

CashFlow Date:

2021-06-30

Investments:

$1.38M

Change To Liabilities:

$425.59K

Total Cashflow From Investing Activities:

$1.38M

Net Income:

$-8,549,079

Total Cash From Operating Activities:

$-8,616,584

Depreciation:

$474.26K

Other Cashflow From Investing Activities:

$1.38M

Change To Inventory:

$-867,587

Change To Account Receivables:

$-115,902

Sale Purchase Of Stock:

$-88,000

Capital Expenditures:

$0

ZLD Income Statement

Income Date:

2021-06-30

Income Before Tax:

$-8,549,079

Net Income:

$-8,549,079

Gross Profit:

$435.09K

Operating Income:

$-9,760,429

Other Operating Expenses:

$108.30K

Interest Expense:

$42.63K

Total Revenue:

$663.32K

Cost Of Revenue:

$228.22K

ZLD Balance Sheet

Balance Sheet Date:

2021-06-30

Intangible Assets:

$1.12M

Total Liabilities:

$1.54M

Total Stockholder Equity:

$37.83M

Total Assets:

$39.37M

Common Stock:

$36.65M

Other Current Assets:

$5.13K

Retained Earnings:

$-27,248,955

Good Will:

$30.75M

Cash:

$4.97M

Total Current Liabilities:

$1.08M

Property - Plant & Equipment:

$1.24M

Net Tangible Assets:

$5.96M

Long-Term Investments:

$166.90K

Total Current Assets:

$6.09M

Net Receivables:

$57.43K

Short-Term Investments:

$33.28M

Inventory:

$867.59K

Accounts Payable:

$0.98M

Short-Term Investments:

$33.28

Non Current Liabilities Total:

$460.55K

ZLD Share Price History

ZLD News

29 Jun, 2021
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
31 Dec, 2020
Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...
15 Dec, 2020
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.